This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marrogi, A. Articles by Gerwin, B. I. Search for Related Content PubMed PubMed Citation Articles by Marrogi, A. Articles by Gerwin, B. I.

Human Mesothelioma Samples Overexpress Both Cyclooxygenase-2 (COX-2) and Inducible Nitric Oxide Synthase (NOS2): In Vitro Antiproliferative Effects of a COX-2 Inhibitor

Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892 [A. M., M. K., L. J. M-B., C. C. H., B. I. G.], and Karmanos Cancer Institute, Wayne State University, Thoracic Oncology Program, Detroit, Michigan 48201 [H. I. P.]

Accumulating data demonstrate overexpression of both inducible NO synthase (NOS2) and cyclooxygenase-2 (COX2) in many epithelial neoplasias. In addition, cyclooxygenase inhibitors have been shown to have antineoplastic and prophylactic efficacy against human colon cancer and in mouse models of this disease. Mesothelioma arises in a context of asbestos exposure and chronic inflammation, which would be expected to enhance the expression of these inducible enzymes. This study demonstrates that both inducible enzymes were expressed in 30 human mesothelioma tissues but were not detectable in nonreactive mesothelial tissues from the same individuals. In contrast, areas of reactive mesothelial cells stained positively for these enzymes. In vitro exposure of human mesothelioma cell lines to the COX2 inhibitor, NS398, revealed dose- and time-dependent antiproliferative activity, whereas the NOS2 inhibitor, 1400W, had no detectable inhibitory effect. Surprisingly, nonmalignant human mesothelial isolates expressed both NOS2 and COX2 in vitro at the same level as mesothelioma cell lines but were less sensitive to NS398 inhibition. This finding indicates that these nonmalignant isolates may retain properties of reactive mesothelial cells and suggests that targets in addition to COX2 may be involved in the antiproliferative response of mesothelioma cell lines. These results have clinical significance because of the selective activity of the drug coupled with the therapeutic resistance and poor prognosis of mesothelioma. The findings presented here suggest that further preclinical studies of these inhibitors in animal models of mesothelioma would be of great interest.

This article has been cited by other articles:

				P. Linscheid, D. Seboek, H. Zulewski, A. Scherberich, N. Blau, U. Keller, and B. Muller Cytokine-induced metabolic effects in human adipocytes are independent of endogenous nitric oxide Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1068 - E1077. [Abstract] [Full Text] [PDF]

				W.-C. Huang, S.-T. Chan, T.-L. Yang, C.-C. Tzeng, and C.-C. Chen Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel {alpha}-methylene-{gamma}-butyrolactone derivatives Carcinogenesis, October 1, 2004; 25(10): 1925 - 1934. [Abstract] [Full Text] [PDF]

				A Baldi, D Santini, F Vasaturo, M Santini, G Vicidomini, M P. Di Marino, V Esposito, A M Groeger, G Liuzzi, B Vincenzi, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma Thorax, May 1, 2004; 59(5): 428 - 433. [Abstract] [Full Text] [PDF]

				P. DeLong, T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda Use of Cyclooxygenase-2 Inhibition to Enhance the Efficacy of Immunotherapy Cancer Res., November 15, 2003; 63(22): 7845 - 7852. [Abstract] [Full Text] [PDF]

				O. Gallo, N. Schiavone, L. Papucci, I. Sardi, L. Magnelli, A. Franchi, E. Masini, and S. Capaccioli Down-Regulation of Nitric Oxide Synthase-2 and Cyclooxygenase-2 Pathways by p53 in Squamous Cell Carcinoma Am. J. Pathol., August 1, 2003; 163(2): 723 - 732. [Abstract] [Full Text] [PDF]

				S. Ekmekcioglu, J. A. Ellerhorst, J. B. Mumm, M. Zheng, L. Broemeling, V. G. Prieto, A. L. Stewart, A. M. Mhashilkar, S. Chada, and E. A. Grimm Negative Association of Melanoma Differentiation-associated Gene (mda-7) and Inducible Nitric Oxide Synthase (iNOS) in Human Melanoma: MDA-7 Regulates iNOS Expression in Melanoma Cells Mol. Cancer Ther., January 1, 2003; 2(1): 9 - 17. [Abstract] [Full Text] [PDF]

				J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862. [Abstract] [Full Text] [PDF]

				A. J. Marrogi, M. A. Khan, H. E. van Gijssel, J. A. Welsh, H. Rahim, A. J. Demetris, K. V. Kowdley, S. P. Hussain, J. Nair, H. Bartsch, et al. Oxidative Stress and p53 Mutations in the Carcinogenesis of Iron Overload-Associated Hepatocellular Carcinoma J Natl Cancer Inst, November 7, 2001; 93(21): 1652 - 1655. [Full Text] [PDF]

				M. ROMANO, A. CATALANO, M. NUTINI, E. D'URBANO, C. CRESCENZI, J. CLARIA, R. LIBNER, G. DAVI, and A. PROCOPIO 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor FASEB J, November 1, 2001; 15(13): 2326 - 2336. [Abstract] [Full Text] [PDF]

				M. Jaiswal, N. F. LaRusso, and G. J. Gores Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis Am J Physiol Gastrointest Liver Physiol, September 1, 2001; 281(3): G626 - G634. [Abstract] [Full Text] [PDF]